EMA Authorised: Fruzaqla (fruquintinib) — Takeda Pharmaceuticals International AG Ireland

View source ↗

Summary

The European Medicines Agency authorised Fruzaqla (fruquintinib) for colorectal neoplasms, with Takeda Pharmaceuticals International AG Ireland as the marketing…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Colorectal Neoplasms

Drugs mentioned

• FRUZAQLA (fruquintinib)

Snippet

Status: Authorised. Therapeutic area: Colorectal Neoplasms. MAH: Takeda Pharmaceuticals International AG Ireland. Decision date: 26/11/2024